Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY.
Related news for (CABA)
- Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
- Today’s Top Performers: MoBot’s Market Review 10/09/25 12:00 PM
- 24/7 Market News Snapshot 09 October, 2025 – Cabaletta Bio, Inc. Common Stock (NASDAQ:CABA)
- MoBot’s Stock Market Highlights – 08/13/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 08/13/25 11:00 AM
